The covalent attachment
of polymers to the surface of proteins
and nanoparticles has been widely employed in the development of biomedical
platforms capable of delaying or diminishing immune surveillance.
The most widely employed polymer for these applications has been poly(ethylene
glycol) (PEG), yet recent evidence has suggested that other polymer
architectures and compositions provide significantly better in vitro
and in vivo properties of protein–polymer hybrid materials.
Moreover, few direct comparisons of PEG to these polymers have been
reported. Here we describe the assembly and characterization of a
series of polymer conjugates of a representative immunogenic viruslike
particle (VLP) using (poly(oligo(ethylene glycol) methacrylate), poly(methacrylamido
glucopyranose), and PEG, and an investigation of their ability to
shield the protein from antibody recognition as a function of polymer
loading density, chain length, architecture, and conjugation site.
Increasing chain length and loading density were both found to significantly
diminish antibody recognition of the VLP conjugates; the conformation
adopted by different polymer architectures was also found to greatly
influence antibody recognition. A direct comparison of these conjugates
to PEGylated VLPs in vivo showed that all formulations gave rise to
similar antibody titers that were significantly diminished relative
to unmodified particles. Interestingly, the quality of the antibody
response was impacted by the properties of the conjugate, with differences
in observed affinity and avidity suggesting a complex dependence on
loading density, chain length, and architecture.